Topical immunomodulation with diphenylcyclopropenone for alopecia areata: The Lebanese experience

International Journal of Dermatology

Volumn 52, Issue 12, 2013, Pages 1551-1556

  El Khoury, Jinane ^a,b   Abd el Baki, Jasmin ^a,b   Succariah, Farah ^a,b   Abbas, Ossama ^a,b   Kibbi, Abdul Ghani ^a,b   Kurban, Mazen ^a,b  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENCYPRONE;

ADULT; ALOPECIA AREATA; ARTICLE; ATOPY; BLISTER; CERVICAL LYMPHADENOPATHY; CLINICAL ARTICLE; CONTACT DERMATITIS; FAMILY HISTORY; FEMALE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; LEBANON; MALE; MEDICAL RECORD REVIEW; PROGNOSIS; PRURITUS; RELAPSE; RETROSPECTIVE STUDY; SCALP;

ADULT; ALOPECIA AREATA; CYCLOPROPANES; FEMALE; HAIR; HUMANS; IMMUNOLOGIC FACTORS; LEBANON; MALE; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84888064830     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12226     Document Type: Article

References (22)

1. Garg S, Messenger AG. Alopecia areata: evidence-based treatments. Semin Cutan Med Surg 2009; 28: 15-18.
2. Safavi KH, Muller SA, Suman VJ, et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995; 70: 628-633.
3. Sellheyer K, Atanaskova-Mesinkovska N, Nelson P, et al. Differential expression of stem cell markers in lichen planopilaris and alopecia areata. Br J Dermatol 2011; 165: 1149-1151.
4. Herbst V, Zoller M, Kissling S, et al. Diphenylcyclopropenone treatment of alopecia areata induces apoptosis of perifollicular lymphocytes. Eur J Dermatol 2006; 16: 537-542.
5. Hoffmann R, Wenzel E, Huth A, et al. Cytokine mRNA levels in alopecia areata before and after treatment with the contact allergen diphenylcyclopropenone. J Invest Dermatol 1994; 103: 530-533.
6. Happle R. Antigenic competition as a therapeutic concept for alopecia areata. Arch Dermatol Res 1980; 267: 109-114.
7. Hull SM, Norris JF. Diphencyprone in the treatment of long-standing alopecia areata. Br J Dermatol 1988; 119: 367-374.
8. Brocker EB, Echternacht-Happle K, Hamm H, et al. Abnormal expression of class I and class II major histocompatibility antigens in alopecia areata: modulation by topical immunotherapy. J Invest Dermatol 1987; 88: 564-568.
9. Happle R, Klein HM, Macher E. Topical immunotherapy changes the composition of the peribulbar infiltrate in alopecia areata. Arch Dermatol Res 1986; 278: 214-218.
10. Wasylyszyn T, Kozlowski W, Zabielski SL. Changes in distribution pattern of CD8 lymphocytes in the scalp in alopecia areata during treatment with diphencyprone. Arch Dermatol Res 2007; 299: 231-237.
11. Simonetti O, Lucarini G, Bernardini ML, et al. Expression of vascular endothelial growth factor, apoptosis inhibitors (survivin and p16) and CCL27 in alopecia areata before and after diphencyprone treatment: an immunohistochemical study. Br J Dermatol 2004; 150: 940-948.
12. Chaturvedi V, Qin JZ, Denning MF, et al. Apoptosis in proliferating, senescent, and immortalized keratinocytes. J Biol Chem 1999; 274: 23358-23367
13. Cotellessa C, Peris K, Caracciolo E, et al. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata. J Am Acad Dermatol 2001; 44: 73-76.
14. Happle R. Diphencyprone for the treatment of alopecia areata: more data and new aspects. Arch Dermatol 2002; 138: 112-113.
15. Wiseman MC, Shapiro J, MacDonald N, et al. Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol 2001; 137: 1063-1068.
16. Olsen EA, Hordinsky MK, Price VH, et al. Alopecia areata investigational assessment guidelines - Part II. National Alopecia Areata Foundation. J Am Acad Dermatol 2004; 51: 440-447.
17. Weise K, Kretzschmar L, John SM, et al. Topical immunotherapy in alopecia areata: anamnestic and clinical criteria of prognostic significance. Dermatology 1996; 192: 129-133.
18. Ohlmeier MC, Traupe H, Luger TA, et al. Topical immunotherapy with diphenylcyclopropenone of patients with alopecia areata - a large retrospective study on 142 patients with a self-controlled design. J Eur Acad Dermatol Venereol 2012; 26: 503-507.
19. El-Zawahry BM, Bassiouny DA, Khella A, et al. Five-year experience in the treatment of alopecia areata with DPC. J Eur Acad Dermatol Venereol 2010; 24: 264-269.
20. Aghaei S. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population. BMC Dermatol 2005; 5: 6.
21. Avgerinou G, Gregoriou S, Rigopoulos D, et al. Alopecia areata: topical immunotherapy treatment with diphencyprone. J Eur Acad Dermatol Venereol 2008; 22: 320-323.
22. Shah M, Lewis FM, Messenger AG. Hazards in the use of diphencyprone. Br J Dermatol 1996; 134: 1153.